Composition from Sphaeranthus indicus and Garcinia mangostana for the control of metabolic syndrome
Pharmaceutical/dietary supplements and food ingredient(s) derived from Sphaeranthus indicus are used for controlling or treating a metabolic disorder. The supplements and food ingredient(s) are selected from Sphaeranthus indicus extract(s), fraction(s), active compound(s) and phytochemical(s) or mixtures thereof and their compositions, preferably in combination with at least one component selected from the extract(s), fraction(s), active compound(s) and phytochemical(s) or mixtures thereof derived from Garcinia mangostana . The ingredients and the composition(s) can be used for the control, prevention and treatment of obesity, metabolic syndrome, diabetes and other metabolic disorders, and also to regulate energy expenditure, prevention of atherosclerotic plaques in coronary artery and abdominal aorta, increase insulin sensitivity, improve glucose tolerance, lower triglyceride levels and balance glucose levels in mammals.
1. A method of controlling or treating a metabolic disorder, comprising administering an effective amount of a biologically active composition to a patient in need thereof,
said biologically active composition comprising effective amounts of:
a first component consisting of:
a.) from 20 to 80 wt. % of an extract of Sphaeranthus indicus flower heads, wherein said extract is at least one of:
a solvent extract obtained by extraction with a solvent selected from the group consisting of: hexane, dichloromethane, chloroform, ethyl acetate, acetone, methanol, ethanol, n-butanol, isopropanol, methyl isobutyl ketone, and mixtures thereof; and
an organic solvent or aqueous solvent extract of Sphaeranthus indicus flower heads, wherein said organic solvent or aqueous organic solvent extract contains from 8% to 21% 7-hydroxyfrullanolide; and
b.) from 20 to 80 wt. % of an organic solvent or aqueous organic solvent extract of Garcinia mangostana fruit rind; and optionally
at least one second component selected from the group consisting of i) biologically active components from plants, animals and microorganisms; ii) pharmaceutically acceptable active ingredients; iii) vitamins; iv) minerals, v) vehicles; vi) carriers; vii) diluents, and viii) mixtures thereof,
wherein the metabolic disorder is selected from the group consisting of diabetes, hypercholesteremia, hyperlipidemia, and a combination thereof.
2. The method of claim 1 , wherein the first component consists of:
from 20 to 80 wt. % of said solvent extract of Sphaeranthus indicus flower heads, wherein said solvent extract is obtained by extraction with a solvent selected from the group consisting of hexane, dichloromethane, chloroform, ethyl acetate, acetone, methanol, ethanol, n-butanol, isopropanol, methyl isobutyl ketone, and mixtures thereof; and
from 20 to 80 wt. % of an organic solvent or aqueous organic solvent extract of Garcinia mangostana fruit rind.
3. The method of claim 1 , wherein said solvent extract of Sphaeranthus indicus flower heads comprises at least one frullanolide or eudesmanoid sesquiterpene compound selected from the group consisting of 7-hydroxyfrullanolide; 11α,13-dihydro-3α,7α-dihydroxy-4,5-epoxy-6β,7-eudesmanolide; 11α,13-dihydro-7α-acetoxy-3β-hydroxy-6β,7-eudesm-4-enolide; 3-keto-β-eudesmol; 11α,13-dihydro-3α,7α-dihydroxyeudesm-4-en-6α,12-olide; 11α,13-dihydro-3α,7α-dihydroxy frullanolide; 11α,13-dihydro-7α,13-dihydroxy frullanolide; 11α,13-dihydro-7α-hydroxy-13-methoxyfrullanolide; 2α,7α-dihydroxy-4-en-11,13-dihydroeudesm-6,12-olide; 2α-hydroxycostic acid; 3-keto-7α-hydroxyeudesm-4-en-6,12-olide (cryptomeridiol); 4-epicryptomeridiol; sphaeranthanolide; 2α-hydroxysphaerantholide; 2α-acetoxysphaerantholide; 2α,7α-dihydroxysphaerantholide; 2α-acetoxy-7α-hydroxysphaerantholide; and 2α-acetoxy-5α-hydroxyisosphaerantholide and mixtures thereof.
4. The method of claim 1 , wherein said extract of Garcinia mangostana fruit rind comprises:
α-mangostin in an amount of from 0.01% to 95%;
γ-mangostin in an amount of from 0.01% to 95%; or
a mixture of α-mangostin and γ-mangostin in an amount of from 0.01% to 95%.
5. The method of claim 1 , wherein said extract of Sphaeranthus indicus flower heads comprises at least one frullanolide or eudesmanoid sesquiterpene compound.
6. The method of claim 1 , wherein said extract of Garcinia mangostana fruit rind inhibits at least one of:
carbohydrate breakdown enzymes selected from the group consisting of alpha-amylase, alpha-glucosidase, and mixtures thereof; and
adipogenesis.
7. The method of claim 1 , wherein the biologically active components from plants, animals and microorganisms have a health benefit selected from the group consisting of anti-diabetic activity, anti-hyperglycemic activity, hypolipidemic activity, anti-obesity activity, anti-hypertensive activity, anti-platelet aggregation activity, anti-infective activity, anti-atherosclerotic activity and antiinflammatory activity, anti-oxidant activity and bio-enhancing activity.
8. The method of claim 1 , wherein the first component consists of:
from 20 to 80 wt. % of said organic solvent or aqueous solvent extract of Sphaeranthus indicus flower heads, wherein said organic solvent or aqueous organic solvent extract contains from 8% to 21% 7-hydroxyfrullanolide; and
from 20 to 80 wt. % of an organic solvent or aqueous organic solvent extract of Garcinia mangostana fruit rind.
9. The method of claim 1 , wherein the first component consists of:
from 25 to 75 wt. % of said solvent extract of Sphaeranthus indicus flower heads, and
from 75 to 25 wt. % of an organic solvent or aqueous organic solvent extract of Garcinia mangostana fruit rind.
10. The method of claim 1 , wherein the first component consists of:
from 33 to 67 wt. % of said solvent extract of Sphaeranthus indicus flower heads, and
from 67 to 33 wt. % of an organic solvent or aqueous organic solvent extract of Garcinia mangostana fruit rind.